Comparative Pharmacology
Head-to-head clinical analysis: PHENERGAN VC versus PYRILAMINE MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENERGAN VC versus PYRILAMINE MALEATE.
PHENERGAN VC vs PYRILAMINE MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenergan VC is a combination of promethazine (a phenothiazine derivative with antihistaminic, sedative, antiemetic, and anticholinergic effects) and phenylephrine (a sympathomimetic amine that acts as a decongestant via alpha-1 adrenergic receptor agonism). Promethazine antagonizes H1 receptors, thereby suppressing allergic reactions and motion sickness. Phenylephrine causes vasoconstriction in the nasal mucosa, reducing congestion.
Pyrilamine is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors, thereby preventing histamine-mediated effects such as increased vascular permeability, vasodilation, and bronchoconstriction.
10-20 mL orally every 4-6 hours as needed; each 5 mL contains 6.25 mg promethazine HCl and 5 mg phenylephrine HCl.
25-50 mg orally every 6-8 hours as needed, not to exceed 200 mg per day.
None Documented
None Documented
9-16 hours; prolonged in hepatic impairment.
Approximately 16-23 hours in healthy adults; may be prolonged in elderly or hepatic impairment.
Renal: 70-80% as metabolites; biliary/fecal: 20-30%.
Primarily renal as metabolites; about 80-90% excreted in urine within 24 hours, with less than 5% unchanged; minor biliary/fecal elimination.
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine